Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

In a first-of-its-kind clinical trial, UCLA scientists have shown it's possible to reprogram a patient's blood-forming stem cells to generate a continuous supply of functional T cells, the immune ...

Production of blood stem cells from reprogrammed adult cells is notoriously difficult. It emerges that a supportive microenvironment may be crucial for their efficient generation. See Article p.312 ...

A recent commentary article published in the New England Journal of Medicine highlights how targeted dietary manipulations could reprogram tumor biology. The possibility that diet could improve cancer ...